This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Cramer's 'Mad Money' Recap: Go Picking Through the Rubble

Stocks in this article: FOSLTSEAZNGAVRTX

Continuing with a third "Executive Decision" segment, Cramer also spoke with John Riccitiello, CEO of Electronic Arts (EA), a stock that's down 30% so far this year, trading at just nine times earnings despite $4 a share in cash on hand.

Riccitiello said that he feels investors will eventually catch up with Electronic Arts' performance, saying that as the company transforms into a larger social and mobile gaming player, investors will see the value. As that change is taking place, however, Riccitiello said that the markets usually discount a stock.

Riccitiello compared his business to that of rival Zynga (ZNGA), a leader in the social and mobile gaming space. He said that while Zynga is a good business, Electronic Arts is a great one with better intellectual property, successes on multiple platforms and franchises like FIFA soccer, John Maddenfootball and The Sims. While Zynga grows through acquisition, said Riccitiello, Electronic Arts can grow organically.

Riccitiello also discounted worries about the company's latest Star Wars release. He said that Star Wars remains a solid success and is a top 10 franchise for the company, but is not in the top five, as some analysts mistakenly expected.

With Electronic Arts expected to release a total of 41 mobile and social apps this year alone, Cramer said that Electronic Arts is among the cheapest stocks he follows.

Eyeing Vertex

Oh what a difference a day makes. That was certainly the case with Vertex Pharmaceuticals (VRTX), a stock that surged 55% yesterday on positive phase II results for the company's latest cystic fibrosis drug. Cramer's take, this speculative stock is still worth buying on any pullback.

The stock gained another 10% today after two more analyst upgrades on the prospects of its treatment for cystic fibrosis. Cramer said with Monday's news, Vertex should be viewed as a completely different company. Last year, his recommendation was based on Vertex' hepatitis C business, but today the company's opportunities to treat cystic fibrosis are all that matters.

So why was Monday's news so important? Cramer said it's because the news was a game changer for the company and it was news that Wall Street was totally not expecting. He said the analysts didn't even factor in the drug's potential after disappointing phase I trials, but now the drug could be a blockbuster.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASDAQ 4,791.63 +4.3130 0.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs